Krzysztof Milewski

Dr. Krzysztof Milewski

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in JACC
Verified
Journal Article
Closed access
Paweł BuszmanPaweł Buszman
Paweł Buszman
SKStefan R. Kiesz
Stefan R. Kiesz
ABAndrzej Bochenek
Andrzej Bochenek
EPEwa Peszek-Przybyla
Ewa Peszek-Przybyla
ISIwona Szkrobka
Iwona Szkrobka
MTMichal Tendera
Michal Tendera

1 February 2016 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Paweł BuszmanPaweł Buszman
Paweł Buszman
PBPiotr P. Buszman
Piotr P. Buszman
IBIwona Banasiewicz-Szkróbka
Iwona Banasiewicz-Szkróbka
KMKrzysztof Milewski
Krzysztof Milewski
AŻAleksander Żurakowski
Aleksander Żurakowski
ABAndrzej Bochenek
Andrzej Bochenek

1 September 2015 in Neurochemistry International
Verified
Journal Article
Closed access
KMKrzysztof Milewski
Krzysztof Milewski
WHWojciech Hilgier
Wojciech Hilgier
JAJan Albrecht
Jan Albrecht
MZMagdalena Zielińska
Magdalena Zielińska

1 October 2009 in JACC
Verified
Journal Article
Closed access
Paweł BuszmanPaweł Buszman
Paweł Buszman
PBPiotr P. Buszman
Piotr P. Buszman
RKR. Stefan Kiesz
R. Stefan Kiesz
ABAndrzej Bochenek
Andrzej Bochenek
BTBlazej Trela
Blazej Trela
MTMichał Tendera
Michał Tendera

1 June 2010 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JGJuan F. Granada
Juan F. Granada
SIShigenobu Inami
Shigenobu Inami
MAMichael S. Aboodi
Michael S. Aboodi
ATArmando Tellez
Armando Tellez
KMKrzysztof Milewski
Krzysztof Milewski
RVRenu Virmani
Renu Virmani
Background—: We aimed to demonstrate that, by separating endothelial progenitor cell capture from sirolimus delivery through the application of drug to the abluminal surface of the stent, the degree of endothelialization can be enhanced. Methods and Results—: Stainless steel R Stents, with biodegradable SynBiosys polymer coating with sirolimus abluminally applied and surface modified with anti-CD34 antibody were prepared at 2 dosages (low-dose sirolimus [LD-Combo, 2.5 μg sirolimus/mm] and full-dose sirolimus [Combo, 5 μg sirolimus/mm). These Combo stents and the Cypher stent (10 μg sirolimus/mm) were deployed in 98 normal porcine arteries and harvested for pharmacokinetic analysis at 0.25, 1, 3, 7, 14, 28, and 35 days. The LD-Combo stents showed faster early release (50%total dose in 72 hours) than the Combo and Cypher. At 30 days, drug release was near complete with both Combo stents, whereas 20% of drug remained on the Cypher stents. To assess efficacy, a total of 50 stents (Xience V=8, Cypher=8, Genous bioengineered R stent=6, LD-Combo=14, and Combo=14) were implanted in 18 pigs for 14 and 28 days. Optical coherence tomography was performed, and stents were harvested for histology. At 28 days, there was less neointimal thickness with Combo (0.173±0.088 mm) compared with Cypher (0.358±0.225 mm), LD-Combo (0.316±0.228 mm), and Xience V (0.305±0.252 mm; P <0.00001). Immunohistochemical analysis of endothelialization showed that Genous bioengineered R stent had the highest degree of platelet endothelial cell adhesion molecule expression (87%) followed by the Combo (75%), LD-Combo (65%), and Cypher (58%). Conclusions—: Both optical coherence tomography and histology demonstrate that anti-CD34 sirolimus-eluting stents promote endothelialization while reducing neointimal formation and inflammation.

9 January 2018 in Circulation
Verified
Journal Article
Open access
PDF file
GSGonca Suna
Gonca Suna
WWWojciech Wojakowski
Wojciech Wojakowski
MLMarc Lynch
Marc Lynch
JBJavier Barallobre-Barreiro
Javier Barallobre-Barreiro
XYXiaoke Yin
Xiaoke Yin
MMManuel Mayr
Manuel Mayr
Background: Extracellular matrix (ECM) remodeling contributes to in-stent restenosis and thrombosis. Despite its important clinical implications, little is known about ECM changes post–stent implantation. Methods: Bare-metal and drug-eluting stents were implanted in pig coronary arteries with an overstretch under optical coherence tomography guidance. Stented segments were harvested 1, 3, 7, 14, and 28 days post-stenting for proteomics analysis of the media and neointima. Results: A total of 151 ECM and ECM-associated proteins were identified by mass spectrometry. After stent implantation, proteins involved in regulating calcification were upregulated in the neointima of drug-eluting stents. The earliest changes in the media were proteins involved in inflammation and thrombosis, followed by changes in regulatory ECM proteins. By day 28, basement membrane proteins were reduced in drug-eluting stents in comparison with bare-metal stents. In contrast, the large aggregating proteoglycan aggrecan was increased. Aggrecanases of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family contribute to the catabolism of vascular proteoglycans. An increase in ADAMTS-specific aggrecan fragments was accompanied by a notable shift from ADAMTS1 and ADAMTS5 to ADAMTS4 gene expression after stent implantation. Immunostaining in human stented coronary arteries confirmed the presence of aggrecan and aggrecan fragments, in particular, at the contacts of the stent struts with the artery. Further investigation of aggrecan presence in the human vasculature revealed that aggrecan and aggrecan cleavage were more abundant in human arteries than in human veins. In addition, aggrecan synthesis was induced on grafting a vein into the arterial circulation, suggesting an important role for aggrecan in vascular plasticity. Finally, lack of ADAMTS-5 activity in mice resulted in an accumulation of aggrecan and a dilation of the thoracic aorta, confirming that aggrecanase activity regulates aggrecan abundance in the arterial wall and contributes to vascular remodeling. Conclusions: Significant differences were identified by proteomics in the ECM of coronary arteries after bare-metal and drug-eluting stent implantation, most notably an upregulation of aggrecan, a major ECM component of cartilaginous tissues that confers resistance to compression. The accumulation of aggrecan coincided with a shift in ADAMTS gene expression. This study provides the first evidence implicating aggrecan and aggrecanases in the vascular injury response after stenting.